| Titre : |
Current Trends in the Pharmacological Treatment of Autism Spectrum Disorders |
| Type de document : |
Texte imprimé et/ou numérique |
| Auteurs : |
Alexander KOLEVZON, Auteur |
| Année de publication : |
2013 |
| Importance : |
p.85-101 |
| Langues : |
Anglais (eng) |
| Index. décimale : |
SCI-D SCI-D - Neurosciences |
| Résumé : |
There has been a significant amount of research into pharmacological treatments in autism spectrum disorders (ASD) over the past several decades. The field has used a targeted symptoms domain approach by borrowing from the existing evidence base in other psychiatric disorders to explore potential treatment effects in ASD. This strategy has been fruitful and led to US Food and Drug Administration (FDA) indications for associated symptoms, including ‘irritability associated with autism’ in the cases of risperidone and aripiprazole. Concurrently, neurobiological evidence has been aggressively pursued and a significant amount of literature has accumulated to describe various biochemical irregularities in ASD. This chapter reviews the current state of evidence in the pharmacological treatment of ASD. Sections are divided into symptom domains, to facilitate ease of clinical use and to describe a rational approach to symptomatic treatment in ASD while arming clinicians with a foundation for making informed treatment decisions. |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=189 |
Current Trends in the Pharmacological Treatment of Autism Spectrum Disorders [Texte imprimé et/ou numérique] / Alexander KOLEVZON, Auteur . - 2013 . - p.85-101. Langues : Anglais ( eng)
| Index. décimale : |
SCI-D SCI-D - Neurosciences |
| Résumé : |
There has been a significant amount of research into pharmacological treatments in autism spectrum disorders (ASD) over the past several decades. The field has used a targeted symptoms domain approach by borrowing from the existing evidence base in other psychiatric disorders to explore potential treatment effects in ASD. This strategy has been fruitful and led to US Food and Drug Administration (FDA) indications for associated symptoms, including ‘irritability associated with autism’ in the cases of risperidone and aripiprazole. Concurrently, neurobiological evidence has been aggressively pursued and a significant amount of literature has accumulated to describe various biochemical irregularities in ASD. This chapter reviews the current state of evidence in the pharmacological treatment of ASD. Sections are divided into symptom domains, to facilitate ease of clinical use and to describe a rational approach to symptomatic treatment in ASD while arming clinicians with a foundation for making informed treatment decisions. |
| Permalink : |
https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=189 |
|
Current Trends in the Pharmacological Treatment of Autism Spectrum Disorders